YE Fei
Principal Investigator
Prof. Ye graduated from Basic Medical College of Beijing Medical University. She has over 30 years of experience in pharmacological investigation focusing on metabolic syndrome based on insulin resistance, especially in exploration of the mechanism and the treatment of glucolipid metabolic disorders and hyperuricemia, and in development of new drugs. During this time, she was engaged in advanced studies at Shiga Medical University in Japan and Servier Research Center in France, respectively. She has published over 70 papers, and has 15 authorized invention patents about new drug development.
1. Exploring and Applying the Substrate Promiscuity of a C-glycosyltransferase in the Chemo-enzymatic Synthesis of Bioactive C-glycosides. Nature Communications, 2020, https://doi.org/10.1038/s41467-020-18990-9.
2. Mangiferin Ameliorates Hyperuricemic Nephropathy Which Is Associated with Downregulation of AQP2 and Increased Urinary Uric Acid Excretion. Frontiers in Pharmacology, 2020, doi: 10.3389/fphar.2020.00049.
3. Urate Transporter URAT1 in Hyperuricemia: New Insights from Hyperuricemic Models. Annals of Clinical & Laboratory Science, 2019, 49(6):756-762.
4. Uncarboxylated osteocalcin ameliorates hepatic glucose and lipid metabolism in KKAy mice via activating insulin signaling pathway. Acta Pharmacologica Sinica, 2019, 41:383–393.
5. Rho, a fraction from Rhodiola crenulat e, ameliorates hepatic steatosis in Mice models. Front. Physiol.-Vascular Physiology Front Physiol. 2018, doi: 10.3389/fphys.2018.00222.
6. A Novel Protein Tyrosine Phosphatase 1B inhibitor with Therapeutic Potential for Insulin Resistance. British Journal of Pharmacology. 2016, 173(12): 1939–1949.
7. Prescription of Jingdan Yimin for treatment of Metabolic syndrome. China Journal of Chinses Materia Medica. 2016,42 (2):272-278.
8. Effect of Hypericum perforatum L. Extract on Insulin Resistance and Lipid Metabolic Disorder in High-Fat-Diet Induced Obese Mice. Phytother Res. 2015, 29(1): 86–92.
9. Investigation of compound, compatibility of Rhodiola crenulate, Cordyceps militaris, and Rhum palmatum, on metabolic syndrome treatment Ⅵ – improving hyperglycemia-mediated renal damage. China Journal of Chinses Materia Medica. 2013, 38(22):3961-6.
10. Investigation of compound, compatibility of Rhodiola crenulate, Cordyceps militaris, and Rhum palmatum, on metabolic syndrome treatment I– improving insulin resistance. China Journal of Chinses Materia Medica. 2012, 37(11):1614-19.
11. Establishment of a screening system for xanthine oxidase (XOD) inhibitors. Chinese Pharmacological Bulletin. 2019,10: 1471-1477.
12. Development of a method to study the activity and selectivity of SGLT2 inhibitors. Acta Pharmaceutica Sinica. 2017, 52 (6): 897 −903.
13. Establishment of an ultrasonographic method for evaluating the hepatic lipid accumulation in mice. Acta Pharmaceutica Sinica. 2014, 49: 1395-1399.
14. The semi-quantitative method for evaluating lipid accumulation in pancreas of diabetic mice. Acta Pharmaceutica Sinica. 2011, 46 (6): 664-668.
15. Utilization of fluorescence tracer in hyperinsulinemic–euglycemic clamp test in mice. J. Biochem. Biophys. Methods, 2008, 70: 978-984.
